A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Christoph K. Stein-Thoeringer,Neeraj Y. Saini,Eli Zamir,Viktoria Blumenberg,Maria-Luisa Schubert,Uria Mor,Matthias A. Fante,Sabine Schmidt,Eiko Hayase,Tomo Hayase,Roman Rohrbach,Chia-Chi Chang,Lauren McDaniel,Ivonne Flores,Rogier Gaiser,Matthias Edinger,Daniel Wolff,Martin Heidenreich,Paolo Strati,Ranjit Nair,Dai Chihara,Luis E. Fayad,Sairah Ahmed,Swaminathan P. Iyer,Raphael E. Steiner,Preetesh Jain,Loretta J. Nastoupil,Jason Westin,Reetakshi Arora,Michael L. Wang,Joel Turner,Meghan Menges,Melanie Hidalgo-Vargas,Kayla Reid,Peter Dreger,Anita Schmitt,Carsten Müller-Tidow,Frederick L. Locke,Marco L. Davila,Richard E. Champlin,Christopher R. Flowers,Elizabeth J. Shpall,Hendrik Poeck,Sattva S. Neelapu,Michael Schmitt,Marion Subklewe,Michael D. Jain,Robert R. Jenq,Eran Elinav
DOI: https://doi.org/10.1038/s41591-023-02234-6
IF: 82.9
2023-03-14
Nature Medicine
Abstract:Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the United States (Germany, n = 66; United States, n = 106; total, n = 172), we demonstrate that wide-spectrum antibiotics treatment ('high-risk antibiotics') prior to CD19-targeted chimeric antigen receptor (CAR)-T cell therapy is associated with adverse outcomes, but this effect is likely to be confounded by an increased pretreatment tumor burden and systemic inflammation in patients pretreated with high-risk antibiotics. To resolve this confounding effect and gain insights into antibiotics-masked microbiome signals impacting CAR-T efficacy, we focused on the high-risk antibiotics non-exposed patient population. Indeed, in these patients, significant correlations were noted between pre-CAR-T infusion Bifidobacterium longum and microbiome-encoded peptidoglycan biosynthesis, and CAR-T treatment-associated 6-month survival or lymphoma progression. Furthermore, predictive pre-CAR-T treatment microbiome-based machine learning algorithms trained on the high-risk antibiotics non-exposed German cohort and validated by the respective US cohort robustly segregated long-term responders from non-responders. Bacteroides , Ruminococcus , Eubacterium and Akkermansia were most important in determining CAR-T responsiveness, with Akkermansia also being associated with pre-infusion peripheral T cell levels in these patients. Collectively, we identify conserved microbiome features across clinical and geographical variations, which may enable cross-cohort microbiome-based predictions of outcomes in CAR-T cell immunotherapy.
biochemistry & molecular biology,cell biology,medicine, research & experimental